Article
Dual-Targeted, Stimuli-Responsive PLGA Nanoparticles for Osteoporosis: Co-Functionalization with Bone- and Osteoclast-Specific Ligands Enables Controlled Risedronate Delivery
2025-04-30
Abstract excerpt
Osteoporosis is a widespread skeletal disease characterized by low bone mass and microarchitectural deterioration, leading to fragile bones and high fracture risk[1]. Current therapies, such as bisphosphonates and RANKL inhibitors, are effective at reducing bone loss but suffer from poor targeting, low oral bioavailability[2], and significant side effects. We propose a novel nanoparticle-based therapeutic strategy...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 995fc5fd-a339-5948-8619-dc7c26556c32
- DOI
- 10.20944/preprints202504.2549.v1
